NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRA-A (vidarabine) is an intravenous antiviral nucleoside analog approved in 1978 for treating serious viral infections. It is primarily indicated for herpes simplex virus (HSV) encephalitis and disseminated varicella-zoster infection in immunocompromised patients. The drug works by inhibiting viral DNA polymerase, preventing viral replication in infected cells.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on cost management and market retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
26 enrolled
Herpes SimplexHIV Infections
Career Relevance
Working on VIRA-A offers minimal growth opportunity and is primarily suited to professionals seeking stable, mature-product experience rather than career acceleration. This role is best for specialists in lifecycle management, specialty care, or rare infection expertise who prioritize work-life balance and deep domain mastery over rapid promotion.
Brand Manager
Worked on VIRA-A at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.